An anaphylactic reaction due to a Hymenoptera sting is a clinical emergency, and patients, their caregivers as well as all healthcare professionals should be familiar with its recognition and acute management. This consensus report has been prepared by a European expert panel of the EAACI Interest Group of Insect Venom Hypersensitivity. It is targeted at allergists, clinical immunologists, internal medicine specialists, pediatricians, general practitioners, emergency department doctors, and any other healthcare professional involved. The aim was to report the scientific evidence on self-medication of anaphylactic reactions due to Hymenoptera stings, to inform healthcare staff about appropriate patient selfmanagement of sting reactions, to propose indications for the prescription of an adrenaline auto-injector (AAI), and to discuss other forms of medication. Firstline treatment for Hymenoptera sting anaphylaxis is intramuscular adrenaline. Prescription of AAIs is mandatory in the case of venom-allergic patients who suffer from mast cell diseases or with an elevated baseline serum tryptase level and in untreated patients with a history of a systemic reaction involving at least two Abbreviations AAI, adrenaline auto-injector; ACE, angiotensin-converting enzyme; BST, baseline serum tryptase; EAACI, European Academy of Allergy and Clinical Immunology; ED, Emergency Department; GRADE, The Grading of Recommendations Assessment, Development and Evaluation; HVA, hymenoptera venom allergy; i.m., intramuscular; i.v., intravenous; ISA, insect sting anaphylaxis; s.c., subcutaneous; SAR, systemic allergic reaction; VIT, venom immunotherapy.
different organ systems. AAI prescription should also be considered in other specific situations before, during, and after stopping venom immunotherapy.
Systemic IgE-mediated reactions to Hymenoptera stings may range from mild symptoms limited to the skin (e.g. generalized pruritus, urticaria) to a fully developed cardiovascular shock with a potentially fatal outcome. Several clinical classifications are in use and reported elsewhere (1) . There is a common agreement that the term anaphylaxis is used only for a severe form of a systemic immediate type reaction if there is involvement of skin or mucosal tissue and respiratory or cardiovascular or gastrointestinal symptoms (2) (3) (4) (5) (6) (7) . It is generally assumed that treatment with adrenaline before the reaction becomes severe improves the chance of survival (8) (9) (10) (11) . Unfortunately, in fatal and near-fatal sting reactions, the time to shock or cardiac/respiratory arrest is short (median 12 min) (8) meaning that timely therapeutic intervention is essential. Today, in many countries, AAIs have become the mainstay of anaphylaxis self-management. Although AAIs appear to be a simple solution, patients are faced with many problems.
It is now 20 years since the original EAACI position paper on the emergency treatment of allergic reactions to Hymenoptera stings was published (12) , and subsequent reports of suboptimal management indicate that an update on this topic is necessary. The objectives of the present document are as follows:
1 To summarize the scientific evidence on which this position paper is based. 2 To inform healthcare staff about appropriate self-management of patients following an anaphylactic reaction to a sting. 3 To propose indications for the prescription of an AAI. 4 To discuss other forms of medication.
This consensus report is targeted at allergists, clinical immunologists, internal medicine specialists, pediatricians, general practitioners, emergency department (ED) doctors, and any other healthcare professional involved.
Materials and methods
This consensus document was prepared by a European Academy of Allergy and Clinical Immunology (EAACI) Task Force, European expert panel of 18 members of the EAACI Interest Group on Insect Venom Hypersensitivity. Data on doctors' intervention, adrenaline's features, and indications for the prescription of an AAI are based on current English literature using a MEDLINE and EMBASE search. The authors used the GRADE system of evaluation to translate the results of this research into evidence-based recommendations (13) (Box 1).
In June 2012, the expert panel discussed the first written draft version of the document. A revised draft was discussed in December 2012 and then in 2013, 2014, and 2015, to achieve group consensus. All issues that received the agreement of ≥94% of the experts were included in the final draft; the same agreement was accepted for an absolute indication for AAI prescription. The authors suggest an update of this consensus document in 2020 unless there are important advances before then.
Anaphylaxis due to insect stings

Definition, pathogenesis, and clinical features
Insect sting anaphylaxis is 'a serious life-threatening generalized/ systemic hypersensitivity reaction which is rapid in onset and might cause death' (2-7) as a consequence of an insect sting.
The pathophysiology of insect sting anaphylaxis (ISA) primarily involves crosslinking of IgE with aggregation of FceRI on mast cells and basophils, which results in a sudden release of preformed and newly generated cell-derived mediators (14, 15) .
Possible alternative or concomitant mechanisms are not completely understood (16), but some evidence shows concomitant activation of complement and activation of the plasma contact system (17, 18) .
At the onset of an individual anaphylactic episode, its course is unpredictable and can result in different clinical patterns (19, 20) : (i) spontaneous resolution due to endogenous counter regulation, (ii) biphasic response, (iii) protracted reaction, and (iv) fatal (usually <6 h after sting). ISA may present with prodromal signs and symptoms or as a fully developed reaction (Table 1) . In children, about 60% of systemic reactions (SARs) are mild and restricted to the skin, whereas in adults, respiratory, or cardiovascular symptoms occur in about 70% of SARs (1). Table 2 shows the risk factors for severe anaphylactic reaction due to insect stings.
Patient's recognition
Patients should be taught which symptoms may forecast a major reaction following a sting in the majority of cases (Table 1) (21) .
In the case of a first event of ISA, a patient may not be aware of its recognition and risk. Unfortunately, around 67% of UK fatal sting reactions occur the first time the patient reacts (22) , limiting the effectiveness of all efforts to prevent fatal reactions. Therefore, widespread information and education of anaphylaxis and its treatment are essential.
Self-treatment of systemic allergic sting reactions
All patients with a previous SAR due to a Hymenoptera sting should be prescribed emergency medications and advised to carry them, especially during the Hymenoptera season (5, 23) .
Aspiration of adrenaline from a vial is time-consuming and the delay may prevent the beneficial effects of the drug; therefore, AAIs are recommended (23) (grade of recommendation D). Several AAI preparations for immediate self-application are commercially available (24-26) (see specific section).
Patients experiencing anaphylaxis should be advised of other interventions needed to manage the reaction. They should be advised to call for help, if possible, and adjust their position according to their leading symptoms: When respiratory distress is leading, they should sit or remain seated, and when symptoms of circulatory instability are leading, they should lie down on their back with the lower extremities elevated (9) (grade of recommendation D).
In addition, patients may receive a set of tablets containing an adequate dose of a rapidly effective nonsedating oral antihistamine (e.g. levocetirizine 10 mg, cetirizine 20 mg, or double dose for children according to the age) and corticosteroids (e.g. prednisone: for adults 50-100 mg and 1-2 mg/kg body weight in children) (4, 6, 12, 27) . For mild SARs, oral antihistamines and corticosteroids are a sufficient treatment. Systemic allergic reactions due to field stings did not occur in patients on VIT taking oral antihistamines and corticosteroids right after the sting before any symptoms have occurred (28) . However, their use should not delay self- Patients with asthma should be advised to carry their inhaled short-acting beta-2-agonist and to use as many inhalations as needed if respiratory difficulty follows a sting (30) (grade of recommendation D). Any patient referred following a sting SAR should be given written recommendations for the avoidance of insect stings as well as a written personalized emergency action (Tables 3 and 4) .
First-line medications
Adrenaline
Even though there is no evidence from prospective, randomized, or quasi-randomized trials on the effectiveness of adrenaline for the emergency management of anaphylaxis mainly due to practical and ethical reasons (31) , there is a universal agreement that adrenaline is the mainstay of therapy to halt the progression of anaphylaxis and to reverse potentially lifethreatening cardiopulmonary manifestations (26, (31) (32) (33) (34) (35) (grade of recommendation C).
Routes of administration and dosage
There have been no prospective human studies performed during the management of anaphylaxis to evaluate the bioavailability and optimal dose of adrenaline given subcutaneously (s.c.), intramuscularly (i.m.), or intravenously (i.v.) (31, 36) . However, according to studies performed in healthy children and adults, adrenaline should be injected by the i.m. route and preferentially in the mid-anterolateral thigh as soon as anaphylaxis is diagnosed or strongly suspected (4, 6, 19, 37) (grade of recommendation A). Given the potentially life-threatening outcome of anaphylaxis, there are no absolute contraindications for the use of adrenaline in the elderly and in patients with preexisting cardiovascular disease or for use in infants or children (6, 20, 37, 38) . Intramuscular adrenaline should be given at a dose of 10 lg per kg of body weight but not exceeding a maximum of 300 lg in children and 500 lg in adults (4, 20, 37) . Depending on the severity of the episode and the response to the initial injection, the dose should be repeated every 5-15 min, as needed (37) . Because of the potential harm from the use of i.v. adrenaline (39) , guidelines generally recommend that the i.v. route has to be given in a resuscitation • Avoid staying in open spaces among plants in bloom (e.g. meadows, orchards), especially when there are mature, ripe fruits on the ground.
• Refrain from eating fruit, sweet jam and jelly, ice-cream and sandwiches outdoors (wasps).
• Keep trash can lids tightly closed, store leftover food in tightly closed containers (wasps).
• Remember, the smell of sweat, any fragrances, and deodorants attract insects, even insect/mosquito repellents.
• Walking barefoot increases the risk of a sting.
• Recommended colors of garments are white, green and beige (brightly colored garments attract insects) (bees)
• While staying at places with an increased risk of exposure to honey bees or wasps, wear long slacks, long-sleeved shirts, hats, and possibly also gloves.
• Do not drink from unattended beer, coke, or other beverages' cans • In case of an attack by wasps or bees, cover your head.
• Do not kill insects without reason-there may be others around.
• Stings are common when working near nests, when attention is focused on the work. Look for signs of nests before starting window cleaning, hedge cutting, trimming, and so on.
• Queen wasps may hibernate in gloves and boots: check these before first use in the winter, even if they were stored in drawers or cupboards. Table 4 Principles of self-management immediately after a sting for patients and caregivers 1 Remove a stinger (if venom sac is still attached).
2 After a sting, immediately take in emergency medication pills in doses prescribed by the physician (antihistamines, glucocorticosteroids). 3 If after a sting, you develop any of the symptoms listed below, despite the administration of medication, you must use an adrenaline auto-injector: After a sting, you develop intense coughing, hoarseness, labored breathing, wheezing, problems with swallowing saliva, speech disturbances, weakness, intense rash, and edema (especially if involving the lips and tongue). 4 Call for help. 5 Sit up if respiratory distress does occur or to lay on back with the lower extremities elevated if you experience symptoms of circulatory instability happen. 6 Following a sting, do not stay alone.
area in cases that do not respond to initial treatment with i.m. adrenaline and where cardiac or respiratory arrest is considered imminent (40) .
Although the use of inhaled adrenaline is not recommended in any form of anaphylaxis, in the event of stridor from laryngeal edema, nebulized adrenaline (2-5 ml, 1 mg/ ml) can be used in addition to i.m. adrenaline (grade of recommendation D).
Negative outcomes
No prospective studies performed during the management of anaphylaxis in humans are available to assess the incidence of adverse effects to adrenaline (31) . When adrenaline has been given in an excessive dose, an inadequately diluted i.v. dose, or an overly rapid rate of infusion, it has been associated with the induction of fatal cardiac arrhythmias, myocardial infarction, and pulmonary edema (8, 39, (41) (42) (43) . Individuals thought to be particularly at risk of adverse effects of adrenaline include elderly patients and patients with hypertension, arteriopathies, or known ischemic heart disease (8, 9) . These patients may also be at increased risk of cardiac problems due to the anaphylactic episode itself (43) (44) (45) . It is difficult, particularly in retrospect, to dissect potentially adverse effects of adrenaline from the known effects of anaphylaxis (8, 38, 41, 46) .
Antihistamines
Systemic and oral anti-H1 antihistamines can be useful in treating mild sting reactions (those limited to skin manifestations, itching, urticaria, angioedema, as well as eye and nasal symptoms) (47) (grade of recommendation B). No high-quality evidence from randomized, controlled trials exists to support the use of H1-antihistamines and H2-antihistamines in the treatment of anaphylaxis (47, 48) . Despite the lack of evidence, it is still recommended in guidelines for the management of anaphylaxis (49) .
Glucocorticosteroids
There is no evidence from randomized, controlled trials to confirm the effectiveness of glucocorticoids in the treatment of anaphylaxis (50, 51) .
They potentially relieve protracted anaphylaxis symptoms and are thought to prevent biphasic anaphylaxis (4, 6, 50, 52), although these effects have never been proven (grade of recommendation D). Other drugs suggested as second-line medications in the treatment of anaphylaxis were described elsewhere (37).
ED doctor intervention
Few studies have examined the management of ISA in the ED or the emergency medical transport system. The results demonstrated that patients with ISA continue to receive care discordant with the guidelines for the emergency management of anaphylaxis. Only a few of the patients received a prescription for AAI or referral to an allergy specialist at ED discharge (53) (54) (55) . Pharmacological treatment of anaphylaxis by ED doctors is not within the scope of this document. However, some practical suggestions are provided below.
1 Because anaphylaxis is often misdiagnosed in ED, it is essential that the clinical record is complete (e.g. blood pressure, pulse, and oxygen saturation). 2 Record the daily medication and any additional self-medication taken on the day of the sting, in particular ACE inhibitor or beta-blocker. 3 Record any additional risk factors for reaction severity such as upright position following onset of shock, supine position in late pregnancy, and so on. 4 For diagnosis of doubtful reactions, collect blood (ideally within 1-2 h but no later than 4 h from the onset of symptoms) for serum tryptase testing (3 ml clotted sample, serum separated and frozen). 5 Patient should be observed for a minimum of 6 h preferably up to 24 h from the beginning of the reaction (37) (grade of recommendation D). In case of patients with a history of biphasic ISA, comorbidities or other risk factors the time of observation should be thoroughly documented. 6 After emergency treatment for suspected ISA, prescribe the patient (or, as appropriate, their parent and/or care givers) an AAI that is appropriate for age and body mass (56) . Patients must receive a referral to a specialist allergy service.
Self-injectable adrenaline
Currently available adrenaline auto-injectors 
Dosage of AAI and needle length
The availability of only two fixed doses of adrenaline represents a problem especially for infants and children allergic to food, as ISA is extremely rare in infants. When using AAI, patients weighing between 7.5 and 25 kg should receive a 0.15 mg dose while those at 25-30 kg should move to 0.3 mg (6, 7, 26) . Even in infants, a 0.15 mg dose is suggested in community settings (62, 63) . However, a large proportion of children <15 kg prescribed an AAI is at risk of having the auto-injector administered into bone. Therefore, AAIs should be prescribed with appropriate counseling in this population (64) . Regardless of the design of the AAI, crucial for efficacy is its needle length, which determines whether the adrenaline goes intramuscularly or subcutaneously ( Table 5 ). The use of currently available AAIs in many women and overweight or obese children may result inadvertently in the s.c. rather than the i.m. deposition (65) (66) (67) (68) . Even the most recently licensed Emerade Ò 0.5 mg and 0.3 mg auto-injectors with an exposed needle length of 25 mm cannot ensure an i.m. injection in all patients (65) . It is recommended to replace the AAI when the solution is discolored or contains a precipitate, and when expiration date is nearing. However, in the first aid treatment of anaphylaxis, if the only AAI available is outdated but free of precipitate, it could be used in preference to no adrenaline injection at all, because it might still have some beneficial effects (69).
Side-effects associated with AAIs
Patients and physicians are sometimes reluctant to use adrenaline early in the course of anaphylaxis because of concerns of potential adverse effects (31) . In a study on the burden of the EpiPen Ò in insect venom-allergic patients, only 20% were concerned about side-effects, while 60% were not after receiving adequate EpiPen Ò instruction (70) . What might be expected about five minutes after i.m. administration of the proper dose are sensation of cold (shivering), trembling, and elevation of the heartbeat. There are no reports about significant adverse effects, such as ventricular arrhythmias, hypertensive crisis, and pulmonary edema, in neither adults nor children using AAIs for the treatment of anaphylaxis. Because of difficulties inherent to patient's emergency selfinjections, the prospect of rapidly disintegrating sublingual tablets is a welcome one.
Indication for prescription of an adrenaline auto-injector
An individual experiencing respiratory or cardiovascular symptom after exposure to a known allergen in the community should receive an AAI immediately and should be instructed in its use (6) .
The first quandary for the physician is to determine which patients who have not actually experienced anaphylaxis as such might also be at risk of anaphylaxis and might also benefit from the prescription of an AAI (71) . In this context, the field of HVA is very peculiar as the prescription of an AAI may be indicated not only in untreated patients with a history of SARs, but also in some already treated with venom immunotherapy (VIT) and in some even after stopping VIT. One concern that might be raised about lowering the threshold for prescribing AAIs is that this may lead to unnecessary adverse effects on the patients' quality of life, because some may view the prescription as the physicians' confirmation of a potentially deadly disease.
Some indications for AAI prescription to patients with HVA have been suggested so far (5, 6, 23, 72) . In clinical practice, these indications differ from country to country and between physicians in the same country, indicating that AAI prescription is a decision that often is made on a case-to-case basis and should include a thorough discussion of the issues involved.
To generate a recommendation for AAI indications in different HVA patients, a questionnaire has been prepared and an analysis of the results has been completed by the HVA expert panel (Table 6 ). Table 7 reports a summary of the recommendations for AAI prescription in patients suffering from HVA that were generated by the expert panel.
Indication for AAI prescription in untreated patients with SAR
According to the available data on the natural history of insect sting allergy in adults, the risk of recurrence of a SAR following a subsequent sting ranges from 20% to 70% (30). Hold your Anapen at the site of injection for 10 s (a slow count to 10) STEP 7 Remove unit from thigh (the orange needle cover will extend to cover needle). Massage the injection site for 10 s
Massage the injection area for 10 s
Gently massage the injection site afterward Call for help (ask for an ambulance and say 'anaphylaxis'). If you are unable to make the call, get someone else to call for you. Do this immediately after using your first pen if you have more than one, even if you now feel better. Do this immediately if you would have used your pen but find you do not have it with you. If the reaction is obviously severe, do not delay using the first pen until after the call for help.
Children with generalized symptoms limited to the skin and mucosa are considered as a low risk group as they have a chance of <10% of a subsequent anaphylactic reaction (73), while those with severe systemic reactions remain at a level of risk as high as 40% after 10 years, and as high as 30% after 20 years (30) . Taking into account these factors, some guidelines (5, 23, 72) state that AAIs should be prescribed for any type of SAR, provided that allergic sensitization has been confirmed by skin testing and/or serum-specific IgE antibodies. The recent EAACI Guidelines on Anaphylaxis (6) state that absolute indications for the prescription of an AAI are as follows: 'venom allergy in adults with SAR (not receiving maintenance VIT) and children with more than cutaneous/ mucosal systemic reactions' as well as 'underlying mast cell disorders or elevated baseline serum tryptase (BST) together with any previous systemic allergic reactions to insect stings, even in VIT treated patients'. Adrenaline prescription should also be considered in the case of 'remote from medical help and previous mild-to-moderate allergic reaction to food, venom, latex, or aeroallergens' (6) .
According to the EAACI expert panel on HVA, adults as well as children with mast cell diseases or elevated BST that have experienced a SAR after an insect sting need an AAI prescription (evidence level IV; grade of recommendation C) (Tables 6 and 7 ). This is also the case when patients have reached the VIT maintenance dose, because of an increased risk of a SAR despite VIT with maintenance dose (74, 75) and the possibility that a SAR may also occur after a sting of an insect of which the venom was not used for VIT (76) . There is also a full agreement on AAI prescription in untreated adults and children with more than skin reactions (evidence level IV; grade of recommendation C) (Tables 6 and 7) .
As for patients with only skin reactions, more than 50% of experts believe that there is no need of an AAI prescription not only in children but also in adults. The only exceptions are cases with high sting exposure (e.g. beekeepers), which can increase the risk of a later progression of SAR severity grade (Table 6) .
Criteria for prescribing an AAI should also consider the quality-of-life issue in the individual patient, because an AAI may be perceived as a burdensome and unsuitable treatment, as reported for the majority of vespid venom-allergic patients with a history of a SAR (77) .
Indication for AAI prescription in VIT-treated patients AAI should always be prescribed until the standard protective maintenance dosage has been reached (78). Its • Children and adults with underlying mast cell disorders or elevated baseline serum tryptase level who experienced any previous systemic reactions, before starting immunotherapy, during, and after stopping VIT (evidence level IV; grade of recommendation C)
• Untreated children and adults with more than cutaneous/mucosal systemic reactions or high risk of reexposure (evidence level IV; grade of recommendation C)
• VIT-treated children and adults with more than cutaneous/mu- prescription during the maintenance phase of VIT remains a controversial issue (5, 72) .
According to the HVA expert panel, there is a full agreement on AAI prescription in treated adults and children with mast cell disorders or elevated BST (evidence level IV; grade of recommendation C), and in patients with more than a dermal reaction if risk factors of VIT failure are present (severe pre-VIT anaphylactic reaction, severe honeybee allergy, anaphylactic reaction during VIT or if VIT efficacy has not been proven by sting challenge or infield sting) (evidence level V; grade of recommendation D) (5, 23, 27, 72) ( Tables 6 and 7) or if the patient is on ACE inhibitor therapy (79) .
As for patients with only skin reactions, about 70-80% of experts believe that there is no need of an AAI prescription in children as well as in adults ( Table 6 ). The only exceptions are cases with high sting exposure (e.g. beekeepers). There may be additional practical or medico-legal considerations as to why some experts do prescribe AAIs in some of these patients.
Indication for AAI prescription after stopping VIT Because of the risk, even if small, of resting reactions, selfadministered emergency medications, including AAIs, should be discussed when stopping VIT (23, 72, 80) . According to the HVA expert panel, there is a full agreement on AAI prescription after stopping VIT in adults and children with mast cell disorders and/or elevated BST (who should usually have prolonged VIT) (evidence level IV; grade of recommendation C), and in adults with more than a dermal reaction if risk factors for relapse are present (e.g. severe honeybee allergy, severity of pre-VIT anaphylactic reaction, anaphylactic reaction during VIT) (81) (evidence level V; grade of recommendation D) (Tables 6 and 7) . In children with a more than cutaneous SAR and in children with risk factors for relapse the vast majority, but not all, of the experts suggest an AAI prescription.
Concerning patients with only dermal reactions (who usually will not receive VIT), more than 80% of experts believe that there is no need of an AAI prescription in children as well as in adults (Table 7) , although the continuing risk of multiple stings related to occupational activities (72) , as well as a short VIT duration and absence of efficacy documentation during VIT (expert panel) should be considered.
AAI prescription in patients with anaphylactic sting reactions and negative testing for venom-specific IgE Even though IgE-negative anaphylaxis has been reported by several investigators, epidemiological data are scarce (82) (83) (84) . The percentage seems to be very low when additional diagnostic tests are performed (e.g., basophil activation test, component-resolved diagnostics). The prescription of an AAI is indicated in patients with underlying mast cell disorders (72, 85, 86) .
It is also indicated in healthy subjects with a documented anaphylactic sting reaction until second allergy work-up within 6 weeks to 3 months later is not performed. The allergy work-up aims to detect positive venom-specific IgE (which were previously negative) due to the boostering effect of the sting.
Large local reactions
Less than 10% of patients with a history of a large local reaction will develop a SAR when next stung, either by a sting challenge or infield sting (87, 88) . According to the vast majority of authors (89) and the HVA expert panel, this risk is considered negligible, making the prescription of an AAI unnecessary (72) .
Indication for prescription of a second adrenaline auto-injector Up to 32% of allergic patients required a further dose of intramuscular adrenaline after the administration of an AAI (6) . The EAACI expert panel agree with the indications for prescription of a second AAI suggested by the EAACI Anaphylaxis Guidelines (6): patients with mast cell diseases and/ or raised BST, previous requirement for more than one dose of adrenaline prior to reaching hospital, previous near-fatal anaphylaxis, lack of rapid access to medical assistance to manage an episode of anaphylaxis due to geographical or language barriers.
Even though it is unclear whether adrenaline administration with auto-injectors may be influenced by a patient's body weight (90) , the recent Anaphylaxis Guidelines suggest a second AAI prescription if available AAI dose is inappropriate for body weight (6).
Patient's compliance and general education
Many studies have shown that compliance with carrying AAI at all times and the ability to correctly administer it are both poor in most patients independent of the cause of anaphylaxis (91) (92) (93) (94) (95) .
Few studies have been performed in HVA patients. In one of these studies, only 18% of bee-allergic beekeepers carried an AAI (96) . Less than 30% of HVA patients carried it at all times (97) . Patients who have not reached the VIT maintenance dose showed a better compliance with carrying the EpiPen Ò (97).
Many HVA patients are unsure when to use their AAI (68) or await for the development of other symptoms before taking any further action (97) despite the instruction of the use tablets immediately after sting and to use AAI if symptoms appear (Table 4) (68) . Only 22% of the patients said that they would immediately administer their EpiPen Ò (97).
Moreover, the majority of the self-medication units were found to be expired when systematically analyzed on followup visits of insect venom-allergic patients in a large allergy outpatient clinic (98) . Therefore, patients and their caregivers should be taught why, when, and how to inject adrenaline and should be equipped with a personalized written anaphylaxis emergency action plan (7) that helps them to recognize anaphylaxis symptoms, instructs them to inject adrenaline promptly, then seek medical assistance, along with appropriate allergen-specific risk reduction measures (Tables 1, 3  and 4) .
Unfortunately, healthcare providers and school personnel have also been shown to be deficient in knowledge concerning the correct administration of AAIs. The above-mentioned findings indicate that further general education is urgently needed.
Conclusions and future perspectives
Hymenoptera sting allergy remains a significant cause of morbidity and mortality all over the world. Currently, there is no way to predict the precise risk of anaphylaxis in vulnerable individuals.
For patients with SARs, prevention of future severe anaphylactic reactions goes through the correct use of adrenaline by the emergency doctors, the prescription of an AAI and most importantly teaching the patient proper techniques for self-administration of adrenaline, and the referral to an allergist for diagnosis and prescription for VIT. However, patients, their caregivers as well as healthcare providers have demonstrated a lack of knowledge on how to use AAIs.
Thus, our efforts should focus on how to improve the general education. Innovative and easy-to-reach methods of education as well as multidimensional approaches are required, especially for adolescents at risk of anaphylaxis to encourage and support self-management of the allergy and reduce risk taking in this group of patients (89, 99) . A better partnership between allergists and emergency physicians would also be helpful (56, 100) .
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